Identification of Potent, Selective, Orally Bioavailable LRRK2 PROTAC® Protein Degraders for the Treatment of Neurodegenerative Diseases
Time: 9:00 am
day: Day 1
Details:
- Spotlighting orally bioavailable, brain penetrant PROTAC® therapies in development for the removal of disease-causing proteins as treatments for neurodegenerative diseases at Arvinas
- Demonstrating how activating mutations in leucine rich repeat kinase 2 (LRRK2) predispose patients to the development of Parkinson’s Disease (PD) and affect the course of disease progression in Progressive Supranuclear Palsy (PSP)
- Identifying and evaluating orally bioavailable, CNS penetrant LRRK2-targeted PROTAC® Protein Degraders
